recombinant human factor VIIa

Recombinant human factor VIIa (rhFVIIa) is a therapeutic coagulation factor and bypassing agent used to treat and control bleeding episodes in patients with hemophilia A or B who have developed inhibitors to Factor VIII or Factor IX. It functions by binding to tissue factor at the site of vascular injury, forming a complex that directly activates Factor X to Factor Xa, thereby bypassing the intrinsic pathway of the coagulation cascade. Major products in this category include **eptacog alfa (activated)**, marketed as NovoSeven by Novo Nordisk, and **eptacog beta (activated)**, marketed as SEVENFACT by Hema Biologics and LFB SA. SEVENFACT is produced using a proprietary rPRO™ technology involving genetically engineered rabbits that express human Factor VII in their mammary glands. rhFVIIa is also indicated for congenital Factor VII deficiency, acquired hemophilia, and Glanzmann's thrombasthenia in specific formulations.

Brand names

SEVENFACTNovoSeven

Other names

eptacog alfa (activated)eptacog beta (activated)Coagulation Factor VIIa RecombinantrhFVIIacoagulation factor VIIa (recombinant)-jncw